NCT01600976View on ClinicalTrials.gov

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

November 30, 2012

Conditions

Hepatic Impairment

Interventions

DRUG

telaprevir

Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.

Trial Locations (2)

Unknown

Prague

Kiel

All Listed Sponsors

lead

Janssen Infectious Diseases BVBA

INDUSTRY

NCT01600976 - A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment | Biotech Hunter | Biotech Hunter